<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543670</url>
  </required_header>
  <id_info>
    <org_study_id>OOS-CANCER-4</org_study_id>
    <nct_id>NCT03543670</nct_id>
  </id_info>
  <brief_title>Evaluation of Oncoxin-Viusid® in Prostate Cancer</brief_title>
  <official_title>Efficacy of Oncoxin-Viusin® Nutritional Supplement Related With the Onco-specific Treatments in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A not randomized clinical survey was done in 25 pacients with histological diagnosis
      confirmed of a prostatic adenocarcinoma and hardy in hormonotherapy at the Calixto Garcia
      Hospital in Habana (2016-2018).

      Researches had as identifying goal the efecctiveness study of Oncoxin-Viusid® nutritional
      supplement as a support to convencional treatment. The patient were treated with habitual
      doses of Docetacel and 75 mg per day of supplement during and fiften day after the
      quimiotherapy. The rest of numbers and severety of adverse reactions were determined as well
      as its influences on life quality when this co-therapy is performed, the evaluation of
      progresion spare survival and the porcentage of recurrences.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2017</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>General quality of life (EORTC QLQ C30 questionnaire and specific for prostate cancer EORTC QLQ - PR25)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Toxicity (hematological, hemochemistry, clinical response) stablished by WHO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overal survival</measure>
    <time_frame>12 months</time_frame>
    <description>Global Survival Rate (GSR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overal recurrences</measure>
    <time_frame>12 months</time_frame>
    <description>Progression-free survival - PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Oncoxin-Viusid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oncoxin-Viusid</intervention_name>
    <description>Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).</description>
    <arm_group_label>Oncoxin-Viusid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Masculine &gt;18 years-old patients

          -  Performans status: Karnofsky ≥ 70 or (ECOG &lt;2)

          -  Hormonal treatment alternatives 6 or 8 weeks before the inclusion ,with resistence to
             hormonal treatments

          -  Normal laboratory tests to onco-specific treatments.

          -  Ecocardiogram with a eyección fraction &gt; 60 %, in patients with history of
             cardiovascular deseases.

          -  Patients with life expectative more than 6 months.

        Exclusion Criteria:

          -  Patients who are receiving another onco-specific product in research.

          -  Patients with known hypersensitivity to anthracyclines and / or mitoxantrone

          -  Decompensated intercurrent diseases, including: active infections, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver damage
             and psychiatric illnesses that could limit adherence to the requirements of the
             clinical trial or any other special condition that at the discretion of the physician
             put your health and life at risk during the study or your participation in the trial.

          -  Patients with cerebral metastases.

          -  Patients with HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercedes I. Fundora, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Calixto García University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Calixto García University Hospital</name>
      <address>
        <city>La Habana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

